Results 31 to 40 of about 1,846,702 (390)

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

Nature Network Boston, 2022
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara—Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that ...
Luca M. Zaeck, M. Lamers, B. Verstrepen, T. Bestebroer, M. V. van Royen, H. Götz, M. Shamier, L. V. van Leeuwen, K. Schmitz, Kimberley Alblas, Suzanne van Efferen, S. Bogers, S. Scherbeijn, G. Rimmelzwaan, E. V. van Gorp, M. Koopmans, B. Haagmans, C. Geurtsvankessel, R. D. de Vries   +18 more
semanticscholar   +1 more source

Phage display selection of HIV specific conserved mimotopes with IgG from long-term non-progressors [PDF]

, 2005
Poster presentation Background The aim of this study is to identify conserved epitopes of HIV-1 neutralizing antibodies in polyclonal plasma from LTNP to finally derive vaccine candidates.
Antoni, Sascha, Dietrich, Ursula, Dittmar, Matthias, Humber, Michael, Rodes, Berta, Schreiber, Andreas, Soriano, Vicente   +6 more
core   +1 more source

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19

Human Vaccines & Immunotherapeutics, 2023
This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and ...
Jia-Lu Feng, Wen-Juan Wang, Peng-Fei Jin, Hui Zheng, Lai-Run Jin, Xin Xia, Xiao-Yin Zhang, Zhuo-Pei Li, Jing-Xin Li, Feng-Cai Zhu   +9 more
doaj   +1 more source

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

New England Journal of Medicine, 2021
BACKGROUND Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the ...
L. Corey, P. Gilbert, M. Juraska, D. Montefiori, L. Morris, S. Karuna, Srilatha Edupuganti, N. Mgodi, Allan C. deCamp, Erika Rudnicki, Yunda Huang, P. Gonzales, R. Cabello, C. Orrell, J. Lama, F. Laher, E. Lazarus, Jorge Sanchez, I. Frank, J. Hinojosa, M. Sobieszczyk, Kyle Marshall, P. Mukwekwerere, J. Makhema, L. Baden, J. Mullins, C. Williamson, J. Hural, M. McElrath, Carter Bentley, Simbarashe Takuva, Margarita M Gomez Lorenzo, D. Burns, Nicole Espy, A. Randhawa, Nidhi K. Kochar, E. Piwowar-Manning, D. Donnell, N. Sista, P. Andrew, J. Kublin, G. Gray, J. Ledgerwood, J. Mascola, M. Cohen   +44 more
semanticscholar   +1 more source

Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes [PDF]

, 2009
Anti-hepatitis C virus (HCV) cross-neutralizing human monoclonal antibodies, directed against conserved epitopes on surface E2 glycoprotein, are central tools for understanding virus-host interplay, and for planning strategies for prevention and ...
Arvind H. Patel, Giovanni Nitti, Giuseppe Sautto, Jonathan K. Ball, Mario Perotti, Massimo Clementi, Nicasio Mancini, Nicola Clementi, Roberta A. Diotti, Roberto Burioni, Sung Key Jang   +10 more
core   +9 more sources

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex [PDF]

, 2017
Human cytomegalovirus (HCMV) is the leading cause of congenital viral infection, and developing a prophylactic vaccine is of high priority to public health.
Adler, Stuart P., An, Zhiqiang, DePhillips, Pete A., Freed, Daniel C., Fu, Tong-Ming, Ha, Sha, Hamm, Melissa, Li, Fengsheng, Loughney, John W., McLellan, Jason S., McVoy, Michael A., Nickle, David C., Rustandi, Richard R., Tang, Aimin, Troutman, Matthew C., Vlasak, Josef, Wang, Dai, Wang, I-Ming, Zhang, Ningyan, Zhu, Hua   +19 more
core   +3 more sources

Neutralizing Antibody Therapeutics for COVID-19 [PDF]

Viruses, 2021
The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. In this article, we review the role of SARS-CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 and provide an overview of recent randomized ...
Hurt, AC, Wheatley, AK
openaire   +5 more sources

Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment

Virology Journal, 2022
Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and ...
Wei Wen, Xinghua Chen, Qiang Lv, Huanchun Chen, Ping Qian, Xiangmin Li   +5 more
doaj   +1 more source

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

Functional stability of HIV-1 envelope trimer affects accessibility to broadly neutralizing antibodies at its apex [PDF]

, 2017
The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs). Env trimer instability and heterogeneity in principle make subunit interfaces inconsistent targets for the ...
Gift, Syna Kuriakose, Kim, Arthur S, Leaman, Daniel P, Zhang, Lei, Zwick, Michael B   +4 more
core   +2 more sources